BackInMed Pharmaceuticals Overview

InMed Pharmaceuticals Receivables

Latest receivables for INM: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
100.00% YoYΔ $-367.81M vs prior year quarter

Peer average

Loading

InMed Pharmaceuticals Receivables History

Loading

InMed Pharmaceuticals vs. peers: Receivables Comparison

Loading

InMed Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

InMed Pharmaceuticals (INM) FAQ

As of the most recent data (March 2026), INM shows a receivables of $0. That compares with $370M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INM's receivables is now $0 (was $370M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether InMed Pharmaceuticals is outperforming or lagging.

Tracking INM's receivables over time shows whether InMed Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $370M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has InMed Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

InMed Pharmaceuticals's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.